
|Articles|February 15, 2004
QLT lowers verteporfin cost after CMS cuts reimbursement
Toronto-QLT Inc. is temporarily lowering the price of verteporfin (Visudyne, Novartis and QLT Inc.) by $55 after the Centers for Medicare & Medicaid Services (CMS) lowered the amount for which it would reimburse physicians.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
New optoretinography technique allows direct measurement of rod function in vivo
2
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
3
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
4
FDA grants breakthrough therapy designation to Oculis’ privosegtor for optic neuritis
5












































